Logo-bi
Editorial
Ghaith Aljayyoussi, Muthanna Abdulkarim, Peter Griffiths, Mark Gumbleton*
Bioimpacts. 2012;2(4): 173-174. doi: 10.5681/bi.2012.029
PMCID: PMC3648940     PMID: 23678457     Scopus ID: 84876813203    
PDF
XML
Cited By:
Original Research
Ayuob Aghanejad, Hiwa Babamiri, Khosro Adibkia, Jaleh Barar ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2018;8(2): 117-127. doi: 10.15171/bi.2018.14
PMCID: PMC6026525     PMID: 29977833     Scopus ID: 85048082430    
Original Article
Mitra Torabi ORCID, Ayuob Aghanejad*, Pouria Savadi ORCID, Abolfazl Barzegari, Yadollah Omidi ORCID, Jaleh Barar* ORCID
Bioimpacts. 2023;13(3): 255-267. doi: 10.34172/bi.2023.25298
PMCID: PMC10329750     PMID: 37431477     Scopus ID: 85158830047    
Owing to their unique advantages, mesoporous silica nanoparticles (MSNPs) have attracted much attention for drug delivery and targeting. In the current study, MSNPs were fabricated, PEGylated, loaded with sunitinib, and conjugated with mucin-16 aptamer to target CA125 on ovarian cancer cells.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge